iBio CFO buys 24,835 shares in open market

iBio, Inc.’s Chief Financial Officer Felipe Duran purchased 24,835 shares of common stock in the open market.

Rhea-AI Filing Summary

iBio, Inc.’s Chief Financial Officer Felipe Duran purchased 24,835 shares of common stock in the open market. The transactions occurred on March 19, 2026 at prices ranging from $2.01 to $2.02 per share, with a weighted average purchase price of $2.0186.

Following these purchases, Duran directly owns 35,974 shares of iBio common stock. The filing notes that the shares were acquired through multiple trades within the price range, and the CFO has committed to provide detailed trade breakdowns upon request.

Insider Trade Summary

Net Buyer: 24,835 shares

Net Buy 1 txn

Insider Duran Felipe

Role Chief Financial Officer

Bought 24,835 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	24,835	$2.0186	$50K

Holdings After Transaction: Common Stock — 35,974 shares (Direct)

Footnotes (1)

1. F1. Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range.

FAQ

What insider transaction did iBio (IBIO) report for its CFO?

iBio reported that Chief Financial Officer Felipe Duran bought 24,835 shares of common stock. The open-market purchases were executed on March 19, 2026 across multiple trades, increasing his direct ownership stake in the company.

At what price did the iBio (IBIO) CFO buy shares?

Felipe Duran purchased iBio common stock at prices between $2.01 and $2.02 per share. The weighted average purchase price for the 24,835 shares acquired was $2.0186, as disclosed in the transaction details.

How many iBio (IBIO) shares does the CFO own after the transaction?

After the reported open-market purchases, Chief Financial Officer Felipe Duran directly owns 35,974 shares of iBio common stock. This post-transaction holding reflects the addition of 24,835 shares bought on March 19, 2026.

Was the iBio (IBIO) CFO’s share purchase an open-market transaction?

Yes. The transaction is classified as an open-market purchase of common stock. The shares were bought in multiple trades within a narrow price range, rather than being part of a grant, option exercise, or non-market transfer.

Does the iBio (IBIO) filing provide detailed trade prices for the CFO purchase?

The filing states that shares were bought between $2.01 and $2.02 with a $2.0186 weighted average. It also notes the CFO will provide full information on the number of shares purchased at each specific price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 07:31 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duran Felipe

(Last) (First) (Middle)

C/O IBIO, INC., 11750 SORRENTO VALLEY

ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		P		24,835	A	$2.0186(1)	35,974	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock purchased by the Reporting Person in multiple transactions at prices ranging from $2.01 through $2.02, inclusive, having a weighted average price as shown in column 4 of $2.0186. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range.

	/s/ Felipe Duran	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)